ImmuCell Corporation — 2011 Form 10-K Summary
Reporting period: Fiscal year ended December 31, 2011; filed March 27, 2012. ImmuCell develops and sells animal-health products for dairy and beef markets. Its main commercial product is First Defense, a calf-scours preventive; Mast Out, an investigational mastitis treatment, remained subject to FDA review.
Financial results and liquidity
| Metric | FY 2011 | FY 2010 | Change |
|---|---|---|---|
| Product sales | $5.111 million | $4.386 million | +17% |
| Gross margin | $2.814 million; 55% of sales | $2.302 million; 52% of sales | +22% margin dollars |
| Operating loss | $633,000 | $690,000 | Loss narrowed |
| Loss before taxes | $697,000 | $683,000 | Loss widened |
| Net loss | $410,000; $0.14 per share | $385,000; $0.13 per share | Loss widened |
| Operating cash flow | $(37,000) | $(809,000) | Cash use fell |
- Fourth-quarter 2011 sales were $1.305 million, up 16% year over year. Gross margin was $725,000; operating income was $9,000, pretax income was $2,000, and net loss was $1,000.
- Cash, cash equivalents and short-term investments totaled $4.960 million at year-end, up $334,000. Net working capital was $6.516 million; total assets were $10.991 million and stockholders’ equity was $9.020 million.
- Year-end bank debt was approximately $1.441 million, comprising current and long-term debt; a $500,000 line of credit was available as needed. Debt is secured by substantially all company assets. A $1 million mortgage is effectively fixed at 6.04% through an interest-rate swap; the $600,000 note has a variable rate. The company reported a $67,900 swap liability.
- Capital expenditures were $244,000. The company stated it had sufficient resources for at least the next 12 months and was required by a debt covenant to maintain at least $1 million in unrestricted cash, cash equivalents and short-term investments.
Changes and operating developments
- First Defense sales increased 21% for the year, including growth in both domestic and international sales. ImmuCell sold its 11-millionth dose during Q4. Product sales overall rose despite an 18% decline in Wipe Out Dairy Wipes sales.
- Gross margin improved to 55% from 52%, above the company’s approximate 50% annual target. Management cited product mix and yield improvements, alongside continuing labor, raw-material and cGMP compliance cost pressures.
- Product-development expense increased 15% to $1.720 million; selling and marketing expense rose 34% to $870,000. Interest expense increased to $81,000 from $22,000.
- ImmuCell recorded its fourth consecutive annual net loss, following nine profitable years through 2007. Sales to two large distributors represented 52% of product sales, and those distributors accounted for 45% of trade receivables at year-end.
Outlook, risks and unusual items
- Management expected positive operating income in 2012, principally based on First Defense sales and reduced product-development spending. This is a forward-looking expectation, not a guaranteed result.
- Completing Mast Out development and bringing it to market was estimated to require approximately $13 million, primarily for manufacturing scale-up and commercial inventory. ImmuCell was seeking partner funding and discussing alternatives; whether a partnership would occur, or on acceptable terms, was unknown.
- Mast Out had received FDA acceptance of pivotal residue data and a zero milk-discard time and zero meat-withhold period, but remained unapproved. FDA review of effectiveness and target-animal-safety submissions continued; the company anticipated further responses in Q2 2012. The manufacturing-controls section was expected to be submitted in Q2 2012, with at least two six-month review cycles anticipated. Final approval and timing were uncertain.
- Key risks include dependence on First Defense, customer and distributor concentration, dairy-industry economics, competition from larger animal-health companies, regulatory and manufacturing delays, reliance on third-party manufacturers, and the possibility that Mast Out funding or approval will not be secured. Management also cited potential market acceptance, pricing and cultured-dairy manufacturing risks for Mast Out.
- The company reported no legal proceedings or off-balance-sheet arrangements. Management assessed disclosure controls and internal control over financial reporting as effective; the auditor did not attest to internal-control effectiveness. The financial statements received an unqualified audit opinion.
Most important facts for investors to verify
- Whether First Defense sales growth and gross margins continued after 2011, and whether the stated 2012 operating-income expectation was achieved.
- Progress, funding terms and total costs for Mast Out, including subsequent FDA decisions, manufacturing plans and any required label or use restrictions.
- Debt balances, covenant compliance, use of the available credit line and the effect of variable interest rates and the swap.
- Exposure to the two largest distributors and reconciliation of the filing’s differing disclosures of 2011 international sales share.
- Realizability of deferred tax assets, including the company’s assumption that future taxable income will support their recovery.